Segmented Islet Cell Scaffolds for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for creating viable islet cells for diabetes treatment face challenges such as limited donor organs, high cell death due to diffusional barriers in large islets, and inefficiencies in culturing beta cells, which hinder effective glycemic control and insulin production.
Innovation Solution
An implantable device with a substantially planar biomaterial scaffold that attaches individual islet cells or small islet cell clusters in a multilayer, using cell adhesion molecules and controlled release of angiogenesis factors, immunosuppressants, and antioxidants to enhance viability and insulin production, while maintaining a uniform thickness to minimize diffusion barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If large islets are used for transplantation, then the number of islet equivalents is increased, but cell death increases due to diffusional barriers in the islet core
Solution Approach 1:
The patent divides large islets into smaller islet clusters or individual islet cells, reducing the diameter from >100 μm to <50 μm. This segmentation maintains the total number of insulin-producing cells while eliminating the diffusional barrier problem that causes core cell death in large islets.
Solution Approach 2:
The patent transitions from three-dimensional large islet structures to two-dimensional monolayer arrangements on scaffold surfaces. This dimensional change increases the surface area-to-volume ratio, improving oxygen and nutrient diffusion throughout the tissue while maintaining cell density and insulin production capacity.
2Quantity of substance
If islet cells are cultured in traditional methods, then beta cell production is achieved, but the process is time-consuming and inefficient
Solution Approach 1:
The patent pre-treats donor pancreases with enzymes and calcium depletion before islet isolation, and pre-prepares scaffold surfaces with adhesion molecules. These preliminary actions accelerate subsequent cell attachment and differentiation, reducing overall culture time while maintaining beta cell yield.
Solution Approach 2:
The patent modifies culture conditions by adding specific adhesion molecules (fibronectin, laminin, vitronectin) to scaffold surfaces and adjusting calcium concentrations during isolation. These parameter changes optimize cell behavior, accelerating maturation to insulin-producing beta cells and reducing culture duration.
3Quantity of substance
If donor pancreases are used for islet isolation, then islet cells can be obtained, but the number of available donors is limited
Solution Approach 1:
The patent creates artificial scaffolds that can be manufactured with standardized adhesion molecule coatings, effectively copying the functional properties of natural pancreatic microenvironment. This allows unlimited production of islet cell carriers without being constrained by donor availability.
Solution Approach 2:
The scaffold acts as an intermediary between donor islet cells and the recipient body. It provides a stable platform that enhances cell survival, differentiation, and integration, effectively amplifying the utility of limited donor material while improving transplant outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves high cell viability and insulin production, with over 85% of islets being less than 50 μm in diameter, resulting in successful transplantation and improved glycemic control by reducing diffusion barriers and enhancing cell survival.
Implementation Method 1
Cell adhesion molecules (e.g. integrins, cadherins, selectins, and immunoglobulins) may be attached to the scaffold to facilitate attachment of individual islet cells or small islet cell clusters to the scaffold
Implementation Method 2
one or more angiogenesis factors, immunosuppressive agents (including autoimmune suppressors), antibiotics, antioxidants, anti-cytokines, or anti-endotoxins may be controllably released from the scaffold to improve viability of the islet cells and small islet cell clusters
Data Source
Figure 1A~1B
Figure 2
Figure 3a
AI summary
A scaffold having islet cells or small islet cell clusters attached thereto in a multilayer, and a micro-mold having divots for culturing islets, wherein islet formation is influenced by the shape and dimensions of the divots are disclosed.